Navigation Links
PAREXEL Advances Early Phase CNS Research Capabilities With Leading Medical Imaging Technology
Date:11/22/2011

BOSTON, Nov. 22, 2011 /PRNewswire/ -- PAREXEL International (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced that it has enhanced its central nervous system (CNS) capabilities for clinical development through the implementation of functional magnetic resonance imaging (fMRI) technology in its Early Phase units. This advanced imaging scanning measures hemodynamic response, or change in blood flow, related to neural activity in the brain or spinal cord. Through this approach, PAREXEL is able to provide sponsors with improved testing paradigms for cognitive biomarkers and better understand the impact of compounds earlier in disease progression.

PAREXEL is among the first to apply this technology broadly to multicenter trials with centralized imaging review processes to improve the quality, consistency and reproducibility of clinical data. This advancement is part of PAREXEL's long-standing commitment to the CNS therapeutic area. The Company has focused on bringing extensive expertise and the latest innovations to early phase drug development, making it a premier provider to biopharmaceutical companies worldwide.

"PAREXEL has continued to provide clients with true leadership in early phase CNS drug development—combining the latest technology with our extensive scientific expertise and CNS research tools, including cerebrospinal fluid dynabridging studies," said Larry Ereshefsky, Pharm. D., F.C.C.P, B.C.P.P., Vice President and Principal Consultant, Early Phase, PAREXEL.

According to Dr. Ereshefsky, "We are helping the biopharmaceutical industry take a major step forward to leverage a
'/>"/>

SOURCE PAREXEL International Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. UCB and PAREXEL Sign Strategic Partnership Agreement
2. PAREXEL International to Present at Lazard Capital Markets Healthcare Conference and Citi Small/Mid Cap Conference
3. PAREXEL Commercialization Experts to Present Best-Practice Approaches for Demonstrating Product Value at ISPOR Annual European Congress
4. PAREXEL Reports First Quarter Fiscal Year 2012 Financial Results
5. PAREXEL Expands Commercialization Capabilities With Dedicated Team to Help Biopharma Companies Demonstrate Product Value
6. New PAREXEL Podcast Series to Deliver Clinical Development and Commercialization Thought Leadership
7. PAREXEL and National University of Singapore Establish Program in Singapore to Meet Increasing Demand in Asia for Clinical Research Talent
8. PAREXEL Announces Date of First Quarter Fiscal Year 2012 Earnings Release and Conference Call
9. Experts to Provide Successful Strategies for Global Biopharmaceutical Development and Commercialization at PAREXEL Tokyo Seminar
10. PAREXEL International Reports Fourth Quarter and Fiscal Year 2011 Results
11. PAREXEL Achieves 100th Asian Ethnobridging Study Milestone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... , a manufacturer of ergonomically designed laboratory equipment for ... Japan to sell and service the Hitachi ... will utilize its network of sales professionals throughout the ... offer assistance in application use, product benefits and features, options and ...
(Date:1/14/2014)... 2014   Oligomerix, Inc. , a privately held company ... disease (AD) and related neurodegenerative disorders, announced today the ... NY as of January 15, 2014 and ... York Medical College. Oligomerix, which is focused ...
(Date:1/14/2014)... 2014   Evidera , a leading provider of evidence-based ... for Drug Evaluation and Research (CDER), U.S. Food and ... document for a patient-reported outcome (PRO) measure in drug ... Tool [EXACT] for Measurement of Symptoms of Acute Bacterial ...
Breaking Medicine Technology:NuAire announces sales and service of Hitachi Koki centrifuges in North America 2Oligomerix Relocates Corporate Headquarters and Secures Additional Laboratory Space from New York Medical College 2Evidera Announces Release of FDA Draft Guidance on Use of the "EXACT" to Measure Symptoms of COPD Exacerbations 2Evidera Announces Release of FDA Draft Guidance on Use of the "EXACT" to Measure Symptoms of COPD Exacerbations 3Evidera Announces Release of FDA Draft Guidance on Use of the "EXACT" to Measure Symptoms of COPD Exacerbations 4
... Feb. 9, 2011 Telik, Inc. (Nasdaq: TELK ... will provide a corporate overview at the 13th Annual BIO ... February 15 at 3:00 p.m. Eastern time (12:00 p.m. Pacific ... archived webcast of the presentation will be available on the ...
... With its governmental markets still depressed, Allied Healthcare Products (Nasdaq: ... of fiscal year 2011 and improvement in its year-over-year performance. ... $117,000, or 1 cent per basic and diluted share, compared to ... For the first two quarters of the fiscal year, net income ...
Cached Medicine Technology:Allied Healthcare Products Reports Modest Profit for Quarter 2Allied Healthcare Products Reports Modest Profit for Quarter 3Allied Healthcare Products Reports Modest Profit for Quarter 4
(Date:4/18/2014)... Hopkins University School of Medicine researchers have been awarded ... diabetes, Novo Nordisk announced this month. Of the 110 ... Obesity Biologics Science Forum Program, only four projects were ... researchers. They are Jonathan Powell, M.D., Ph.D.; G. William ... Jonathan Powell, a professor of oncology, will use his ...
(Date:4/18/2014)... Benaroya Research Institute at Virginia Mason (BRI) recently received ... in metastatic breast cancer reduces both the growth of ... scientists have found in models of the disease that ... 80 percent and can keep the tumor from metastasizing ... grant comes from the National Cancer Institute of the ...
(Date:4/18/2014)... 2014) ― A new study in the American ... health-related Google searches reveals a recurring pattern that could ... , Investigators from San Diego State University, the Santa ... analyzed "healthy" Google searches (searches that included the term ... in the U.S. from 2005 to 2012. They found ...
(Date:4/18/2014)... scientists could lead to potential new treatments for breaking ... , Fibrosis, or scarring, is a hallmark of ... lungs can lead to serious organ damage and, in ... options centers on findings made by Swati Bhattacharyya, PhD, ... that a specific protein plays in promoting fibrosis. ...
(Date:4/17/2014)... of chronic inflammation in non-cancerous prostate tissue may have ... than those with no inflammation, according to results of ... Hopkins Kimmel Cancer Center. , The link between persistent ... so-called high-grade prostate cancer those with a Gleason ... of the most aggressive and rapidly growing prostate cancers. ...
Breaking Medicine News(10 mins):Health News:Benaroya Research Institute evaluates immunology approach to blocking breast cancer 2Health News:New research shows people are thinking about their health early in the week 2Health News:New clues on tissue scarring in scleroderma 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3
... claiming that the she admitted to being an alcoholic. ... was made up and not written by her. ... Contactmusic quoted Allen, as saying. ,The Smile singer revealed ... was misinterpreted by someone and was spread wrongly. ,"I ...
... smoking rate has shown a decline, thanks to the comprehensive ... statistics in the 2006 report shows a decline in ... ,Over the past year, smoking decreased among men (from ... These large declines followed a year-long ad campaign aimed at ...
... detecting and measuring all known forms of hepatitis B ... patient therapy. ,Abbott and Celera, an Applera ... marking for a real-time PCR (polymerase chain reaction) test ... allowing the test to be marketed in the European ...
... Purdue university researchers has found a new modified drug for ... clinical trials. ,Millions of people suffer from ... Arun Ghosh, the Purdue professor who led the creation of ... could be the first disease-modifying therapy. It may be able ...
... Pennsylvania School of Medicine have identified proteins in the rod ... discovery of the genetic causes of a host of ... understanding of what goes wrong at the most basic level ... ,Specifically, they have identified and measured the types and ...
... study, published in The American Journal of Gastroenterology, indicates ... and 304 patients has confirmed that polyethylene (PEG) ... even elderly patients can use the drug safely for ... few data were available regarding the long term treatment ...
Cached Medicine News:Health News:New York Records Decline in Smoking Rate 2Health News:Abbott's RealTime Hepatitis B Viral Load Test Receives CE Marking in Europe 2Health News:Abbott's RealTime Hepatitis B Viral Load Test Receives CE Marking in Europe 3Health News:Modified Drug Therapy for Alzheimers Disease 2Health News:Genetic Cause of Inherited Eye Diseases Identified 2
For the quantitative determination of total cholesterol in serum....
Intended for the quantitative determination of total cholesterol in serum. Reaction: Endpoint. Reaction complete within five minutes. Wavelength: 500 nm. Linearity: 700 mg/dL (18.1 mmol/L). Single st...
... determination of Cholesterol in serum. ... 520 nm. Linearity: 500 mg/dl. ... simple 1:25 dilution and is ... 2-8 C. Liquid kit stability: ...
This 16-bit integrated and cooled system is a completely self contained unit built with a long list of standard features including all-electronic-variable transilluminator and EPI lighting....
Medicine Products: